LIU Longchao----微生物研究所

CAS Key laboratory of Pathogenic Microbiology & Immunology

Your current location: Home > People > Principal Investigators > CAS Key laboratory of Pathogenic Microbiology & Immunology

Principal Investigator,Professor : Cancer immunotherapy and T-cell immunity

LIU Longchao

Title：PhD, Professor

Dept.:CAS Key Laboratory of Pathogenic Microbiology and Immunology

Address：NO.1 Beichen West Road, Chaoyang District, Beijing 100101, P. R. China

Telephone/fax：+86-10-

E-mail：liulongchao@im.ac.cn

Research Interests

1. Engineering bispecific antibodies and cytokines for cancer immunotherapy.
2. Investigate the mechanism of T-cell exhaustion.
3. Identify novel cancer immunotherapy targets.

Education/degrees

2011-2016 Ph.D. in Biochemistry and Molecular Biology, University of Chinese Academy of Sciences
2007-2011 B.S. in Biotechnology, Jilin University

Work experience

Post-doctoral fellow training
2017.2-2022.11 Dr. Yang-Xin Fu’Lab, UT Southwestern Medical Center, Dallas, TX, USA
Professional Appointments
2023.1-present Principal Investigator, Professor and Ph.D. advisor, IMCAS

Awards

2018 AAI Trainee Poster Award, UT Southwestern Medical Center.
2015 The Merit Student, University of Chinese Academy of Sciences.
2011 The First Prize Scholarship, Jilin University.
2011 The Excellent Student Cadre, Jilin University.
2008 The Excellent Student, Jilin University.
2008 National Scholarship, Jilin University.

The main research areas

Mechanism of T-cell exhaustion, cancer immunotherapy strategies and tumor microenvironment.

Publication

1. Bae J^#, Liu L^#, Moore C#, Hsu E, Zhang A, Ren Z, et al. IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8(+) T cells to overcome immunotherapy resistance in cancer. Nat Cell Biol 2022;24:1754-1765.

2. Liu L^#, Chen J^#, Zhang H#, Ye J, Moore C, Lu C, et al. Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity. Nat Cancer 2022;3:437-452.

3. Liu L, Chen J, Bae J, Li H, Sun Z, Moore C, et al. Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells. Nat Biomed Eng 2021;5:1261-1273.

4. Zhang H^#, Liu L^#, Zhang J, Chen J, Ye J, Shukla S, et al. Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers. Clin Cancer Res 2020;26:1359-1371.

5. Liu X^#, Liu L^#, Ren Z, Yang K, Xu H, Luan Y, et al. Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion. Cell Rep 2018;24:2101-2111.

6. Zhu D^#, Liu L^#, Yang D, Fu S, Bian Y, Sun Z, et al. Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination. J Immunol 2016;196:3079-3087.

7. Yang D^#, Liu L^#, Zhu D, Peng H, Su L, Fu YX, et al. A mouse model for HBV immunotolerance and immunotherapy. Cell Mol Immunol 2014;11:71-78.

Co-author

1. Moore C, Bae J, Liu L, Li H, Fu YX, Qiao J. Exogenous signaling repairs defective T cell signaling inside the tumor microenvironment for better immunity. JCI Insight 2022;7.

2. Li H, Liu Z, Liu L, Zhang H, Han C, Girard L, et al. AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1(+) CD8 T cells. Cell Rep Med 2022;3:100554.

3. Lu C, Guan J, Lu S, Jin Q, Rousseau B, Lu T, Stephens D, Zhang H, Zhu J, Yang M, Ren Z, Liang Y, Liu Z, Han C, Liu L, Cao X, Zhang A, Qiao J, Batten K, Chen M, Castrillon DH, Wang T, Li B, Diaz LA, Jr., Li GM, Fu YX. DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. Cancer Cell 2021;39:96-108 e106.

4. Han C, Godfrey V, Liu Z, Han Y, Liu L, Peng H, et al. The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation. Sci Immunol 2021;6.

5. Deng S, Sun Z, Qiao J, Liang Y, Liu L, Dong C, et al. Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells. JCI Insight 2020;5.

6. Liu Z, Han C, Dong C, Shen A, Hsu E, Ren Z, Lu C, Liu L, Zhang A, Timmerman C, Pu Y, Wang Y, Chen M, Qiao J, Fu YX. Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. Sci Immunol 2019;4.

7. Yang K, Liang Y, Sun Z, Liu L, Liao J, Xu H, et al. T cell-derived lymphotoxin limits Th1 response during HSV-1 infection. Sci Rep 2018;8:17727.

8. Bian Y, Zhang Z, Sun Z, Zhao J, Zhu D, Wang Y, Fu S, Guo J, Liu L, Su L, Wang FS, Fu YX, Peng H. Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice. Hepatology 2017;66:1067-1082.